Dengue Fever Maintains Elevated Global Transmission in 2026

Overview

Dengue fever, a mosquito-borne viral illness caused by any of four distinct serotypes of the dengue virus, continues to circulate at persistently high levels across tropical and subtropical regions of the world. The European Centre for Disease Prevention and Control (ECDC) publishes a monthly global epidemiological overview of dengue transmission as part of its Communicable Diseases Threat Report series, providing one of the most systematic international surveillance snapshots available to public health professionals and policymakers.

As of the most recent reporting period through late March 2026, global dengue activity remains a significant public health concern. The disease, transmitted primarily by the Aedes aegypti mosquito — and to a lesser extent Aedes albopictus — does not respect borders, and the combination of climate change expanding mosquito habitat, urbanization, and high international travel volumes has made dengue a genuinely global problem rather than a purely regional one.

For European and North American readers, dengue may seem geographically distant, but it is increasingly relevant: imported cases in non-endemic countries have risen steadily over the past decade, and local transmission has been documented in southern Europe, particularly in France, Italy, and Spain, where Aedes albopictus (the tiger mosquito) is now well established.

Current Situation

Image: Wikimedia Commons

The ECDC’s monthly dengue surveillance synthesizes data from WHO regional offices, national health ministries, and open-source outbreak intelligence platforms to construct a rolling picture of global transmission intensity. While the March 2026 monthly report continues routine monitoring rather than signaling an acute emergency, the broader trajectory of dengue over the past several years demands ongoing vigilance.

Globally, the WHO has reported that dengue cases have increased approximately eightfold over the past two decades, with an estimated 100 to 400 million infections occurring annually worldwide, though the vast majority are mild or asymptomatic and go undetected. Reported clinical cases represent only a fraction of true burden.

Severe dengue — including dengue hemorrhagic fever and dengue shock syndrome — carries a case fatality rate that can exceed 2–5% without adequate clinical management, but drops to below 1% with proper supportive care and early recognition. The critical public health challenge is that dengue’s initial symptoms (high fever, severe headache, pain behind the eyes, muscle and joint pain, nausea) closely mimic other febrile illnesses, making early diagnosis and triage difficult in resource-limited settings.

Seasonal peaks vary by region: “global”

Affected Regions

Dengue’s global footprint is broad, with the Americas, Southeast Asia, and the Western Pacific consistently accounting for the largest share of reported cases.

In the Americas, Brazil historically drives the regional burden and continues to do so, with multi-serotype co-circulation creating conditions for more severe disease in previously infected individuals. Countries including Colombia, Argentina, Peru, and several Caribbean nations also report sustained transmission. The Americas have experienced historically unprecedented dengue seasons in consecutive years, partly attributed to expanding Aedes aegypti range driven by warming temperatures.

Southeast Asia — including the Philippines, Vietnam, Thailand, Malaysia, Indonesia, and Bangladesh — remains one of the world’s most affected sub-regions. Urban density, standing water in informal settlements, and high population movement all contribute to year-round transmission pressure. The simultaneous circulation of multiple dengue serotypes increases the population’s exposure to secondary infections, which carry a substantially higher risk of severe disease due to antibody-dependent enhancement.

South Asia, particularly India and Sri Lanka, reports significant seasonal burdens, though surveillance infrastructure variability means reported figures likely underrepresent true incidence.

In Africa, dengue surveillance has historically been weaker, leading to systematic undercounting. However, expanding surveillance networks and improved diagnostic capacity have revealed dengue to be far more prevalent across sub-Saharan Africa than previously recognized, with outbreaks documented in countries including Sudan, Burkina Faso, Tanzania, and Senegal.

For travelers departing to any dengue-endemic region, personal mosquito bite prevention is the single most important protective measure — no medication prevents infection, and vaccine access outside endemic countries remains extremely limited.

Within Europe, the ECDC maintains heightened surveillance for both imported cases in returning travelers and for locally acquired transmission in southern European countries where competent vector mosquitoes are established. Italy, France, Croatia, and Spain have all documented autochthonous (locally acquired) dengue transmission events in recent years, and this pattern is expected to expand as tiger mosquito populations grow northward.

Risk Assessment

The WHO does not currently designate a single global dengue emergency, but it classifies dengue as one of the top ten threats to global health and maintains it as a priority disease under the R&D Blueprint for epidemic preparedness. The overall global risk level for dengue in 2026 is assessed as moderate to high, consistent with the prior several years.

Several structural factors sustain this risk assessment:

Serotype diversity and secondary infection risk. There are four dengue serotypes (DENV-1 through DENV-4), and infection with one confers lifelong immunity only to that type. Subsequent infection with a different serotype significantly increases the risk of severe dengue through immune mechanisms. In regions where multiple serotypes co-circulate, the epidemiological risk profile is substantially worse.

Climate and vector expansion. Warming temperatures and altered precipitation patterns are extending the viable habitat range of Aedes aegypti and Aedes albopictus into previously non-endemic zones, including higher elevations and higher latitudes. This is not a future scenario — it is already observable in European vector surveillance data.

Urbanization. Rapid, unplanned urban growth in tropical low- and middle-income countries creates ideal breeding conditions for container-breeding Aedes mosquitoes: discarded tires, open water storage vessels, flower pot saucers, and construction sites all provide larval habitat.

Vulnerable populations. Infants under one year of age, elderly individuals, those with underlying conditions (diabetes, cardiovascular disease, obesity), and those experiencing secondary heterologous dengue infections face the highest risk of severe outcomes. Pregnant women with dengue face elevated risks of adverse pregnancy outcomes.

Prevention & Response

No single intervention has proven capable of eliminating dengue, and public health responses operate across multiple layers simultaneously.

Vaccines. The Sanofi Pasteur dengue vaccine Dengvaxia (CYD-TDV) is licensed in several endemic countries for seropositive individuals aged 9–45, but its use is carefully restricted because administration to dengue-naive individuals increases severe disease risk in first infections. A second vaccine, Takeda’s Qdenga (TAK-003), has received approval in the EU, Indonesia, and several other countries and shows efficacy against multiple serotypes in both seropositive and seronegative individuals, representing a meaningful advance. Neither vaccine is widely available to travelers from non-endemic countries through standard travel medicine programs.

Vector control remains the backbone of dengue prevention. Integrated vector management programs combine larval source reduction (eliminating standing water), insecticide application (indoor residual spraying, space spraying during outbreaks), and community-level behavior change campaigns. The WHO advocates for evidence-based vector control as a public health priority, noting that insecticide resistance in Aedes aegypti populations is an emerging constraint.

Novel biocontrol methods, including the release of Wolbachia-infected mosquitoes (which reduce the ability of Aedes aegypti to transmit dengue) by the World Mosquito Program, have shown promising results in randomized trials in Indonesia and Australia, and deployment is expanding in several endemic countries.

At the clinical level, early diagnosis using rapid NS1 antigen tests, appropriate fluid management, and timely escalation of care for warning signs (severe abdominal pain, persistent vomiting, bleeding, rapid breathing) are the interventions that most directly reduce fatality rates.

The ECDC advises European travelers to endemic regions to use DEET or picaridin-based repellents, wear long sleeves and trousers during peak mosquito activity hours, use permethrin-treated clothing for extended stays, and sleep under insecticide-treated nets. Travelers developing febrile illness within two weeks of return from an endemic country should inform their clinician of travel history.

---

Sources

• European Centre for Disease Prevention and Control (ECDC) — Dengue Worldwide Overview (monthly): https://www.ecdc.europa.eu/en/dengue-monthly
• World Health Organization (WHO) — Dengue and Severe Dengue Fact Sheet
• WHO — Communicable Diseases Threat Report (CDTR), weekly series
• Takeda Pharmaceuticals — Qdenga (TAK-003) vaccine approval documentation
• World Mosquito Program — Wolbachia dengue biocontrol program data